Phase 2
N=22
Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Bottom Line
View on ClinicalTrials.gov: NCT00581854 ↗Enrolled (actual)
22
Serious AEs
36.4%
Results posted
Jul 2014
Primary outcome: Primary: Complete Response Rate to Induction Therapy — 64 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- modified Hyper-CVAD (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Wisconsin, Madison
- Primary completion
- Jun 2006
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Complete Response Rate to Induction Therapy |
64 | — |
Summary
rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
Eligibility Criteria
Inclusion Criteria
- Untreated mantle cell lymphoma
Exclusion Criteria
- Pregnant or breast feeding
Data sourced from ClinicalTrials.gov (NCT00581854). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.